Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received for publication November 26, 2012
- Accepted for publication January 28, 2013
- Published online July 1, 2013.
Article Versions
- previous version (May 7, 2013 - 11:16).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2013 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
Author Information
- Sietske B.M. Gaykema1,
- Adrienne H. Brouwers2,
- Marjolijn N. Lub-de Hooge2,3,
- Rick G. Pleijhuis4,
- Hetty Timmer-Bosscha1,
- Linda Pot1,
- Gooitzen M. van Dam4,
- Sibylle B. van der Meulen5,
- Johan R. de Jong2,
- Joost Bart6,
- Jakob de Vries4,
- Liesbeth Jansen4,
- Elisabeth G.E. de Vries1 and
- Carolien P. Schröder1
- 1Department of Medical Oncology, University Medical Center Groningen, Groningen, The Netherlands
- 2Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, The Netherlands
- 3Department of Hospital and Clinical Pharmacy, University Medical Center Groningen, Groningen, The Netherlands
- 4Department of Surgical Oncology, University Medical Center Groningen, Groningen, The Netherlands
- 5Department of Radiology, University Medical Center Groningen, Groningen, The Netherlands; and
- 6Department of Pathology, University Medical Center Groningen, Groningen, The Netherlands
- For correspondence or reprints contact: Carolien P. Schröder, Department of Medical Oncology, University Medical Center Groningen, P.O. Box 30001, 9700 RB Groningen; the Netherlands. E-mail: C.P.Schroder{at}umcg.nl
Statistics from Altmetric.com
Cited By...
Article usage
89Zr-Bevacizumab PET Imaging in Primary Breast Cancer
Jump to section
Related Articles
Cited By...
- 89Zr-Immuno-PET: Toward a Noninvasive Clinical Tool to Measure Target Engagement of Therapeutic Antibodies In Vivo
- 89Zr-oxine labelling and PET imaging shows lung delivery of a cell/gene cancer therapy
- A Distinct Advantage to Intraarterial Delivery of 89Zr-Bevacizumab in PET Imaging of Mice With and Without Osmotic Opening of the Blood-Brain Barrier
- Near-infrared fluorescence molecular endoscopy detects dysplastic oesophageal lesions using topical and systemic tracer of vascular endothelial growth factor A
- PET Imaging of Receptor Tyrosine Kinases in Cancer
- Tracers for Fluorescence-Guided Surgery: How Elongation of the Polymethine Chain in Cyanine Dyes Alters the Pharmacokinetics of a Dual-Modality c[RGDyK] Tracer
- Pharmacokinetics, Biodistribution, and Radiation Dosimetry for 89Zr-Trastuzumab in Patients with Esophagogastric Cancer
- 89Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors
- The Use of Microdosing in the Development of Small Organic and Protein Therapeutics
- Tumor-Specific Uptake of Fluorescent Bevacizumab-IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study
- 89Zr-Bevacizumab PET: Potential Early Indicator of Everolimus Efficacy in Patients with Metastatic Renal Cell Carcinoma
- 89Zr-Bevacizumab PET Visualizes Disease Manifestations in Patients with von Hippel-Lindau Disease
- ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody-Drug Conjugate Treatment
- The Use of Novel PET Tracers to Image Breast Cancer Biologic Processes Such as Proliferation, DNA Damage and Repair, and Angiogenesis
- ADAPT, a Novel Scaffold Protein-Based Probe for Radionuclide Imaging of Molecular Targets That Are Expressed in Disseminated Cancers
- Antibody Positron Emission Tomography Imaging in Anticancer Drug Development
- Role of Positron Emission Tomography for the Monitoring of Response to Therapy in Breast Cancer
- 89Zr-Bevacizumab PET Visualizes Heterogeneous Tracer Accumulation in Tumor Lesions of Renal Cell Carcinoma Patients and Differential Effects of Antiangiogenic Treatment
- A Modular Labeling Strategy for In Vivo PET and Near-Infrared Fluorescence Imaging of Nanoparticle Tumor Targeting
- 89Zr-trastuzumab and 89Zr-bevacizumab PET to Evaluate the Effect of the HSP90 Inhibitor NVP-AUY922 in Metastatic Breast Cancer Patients
- Everolimus Reduces 89Zr-Bevacizumab Tumor Uptake in Patients with Neuroendocrine Tumors
- Development of a Radiolabeled Irreversible Peptide Ligand for PET Imaging of Vascular Endothelial Growth Factor
- Glypican-3-Targeted 89Zr PET Imaging of Hepatocellular Carcinoma: Where Antibody Imaging Dares to Tread
- CNS Metastases in Breast Cancer: Old Challenge, New Frontiers